All studies
Phase 3RecruitingInterventionalNCT07140913

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

  • Mania
  • Bipolar Disorder
I want to take partRefer a patient5 sites in India (4 recruiting) · 109 worldwide

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
Bristol-Myers Squibb
Enrolment target
424
Started
8 October 2025
Main results due (estimated)
28 June 2027
Study ends (estimated)
28 June 2027
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
Double (participant, investigator)
Sites
109 · 5 in India
First posted
26 August 2025
Registry updated
3 November 2026

Can you take part?

  • Ages 18 years to 65 years.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* Individuals have a primary diagnosis of Bipolar-I disorder established by a comprehensive psychiatric evaluation based on the DSM-5-TR criteria and confirmed by the Mini International Neuropsychiatric Interview (MINI) version 7.0.2.
* Individual is experiencing an acute exacerbation or relapse of manic episode, with or without mixed features (≤ 3 weeks).
* The individual requires hospitalization for the acute exacerbation or relapse of mania.
* Body mass index ≥ 18 and ≤ 40 kg/m2.
* Currently experiencing an acute episode of mania or mania with mixed features with a therapeutic dose of lithium, valproate, or lamotrigine. The dose of the mood stabilizer must have remained stable for at least two weeks prior to screening. Additionally, participants on valproate must have been receiving treatment with valproate for a minimum of seven months.
* YMRS Total Score of ≥ 18 at Screening and at Baseline, and \< 20% reduction in YMRS from screening to baseline.

Exclusion Criteria:

* Any primary DSM-5-TR disorder other than BP-I within 12 months before screening (confirmed using MINI version 7.0.2 at screening) including BP-I depression (for previous 3 months only), BP-I with rapid cycling, first manic episode, BP-II, primary psychotic disorder, borderline personality disorder, and major depressive disorder, with the exception of mild anxiety disorders.
* Individual has a DSM-5-TR diagnosis of moderate to severe substance use disorder (except tobacco use disorder) within the 12 months before screening (confirmed using MINI version 7.0.2 at screening), or current use as determined by urine toxicology screen or alcohol test.
* Risk for suicidal behavior at screening as determined by the investigator's clinical assessment and the C-SSRS with an answer "Yes" to item 4 or 5 within 6 months before screening or between screening and baseline, or "Yes" to any of the 5 items (C-SSRS behavior) with an event occurring within the 12 months before screening, or between screening and baseline.
* History of irritable bowel syndrome (with or without constipation) or any serious constipation requiring treatment within the last 6 months.
* History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma.
* Participants with HIV, cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections based on either medical history or the LFT results.
* Elevations in hepatic transaminases at screening ≥ 2 × ULN for ALT or AST and/or bilirubin \> 1.5× ULN, unless in the context of Gilbert's syndrome.
* All grades of hepatic impairment (mild \[Child-Pugh Class A\], moderate \[Child-Pugh Class B\], and severe \[Child-Pugh Class C\]).
* Other protocol-defined Inclusion/Exclusion criteria apply.

What this study is about

In the sponsor’s own words, from the registry.

The purpose of this study is to evaluate the efficacy and safety of adjunctive KarXT for the treatment of mania in participants with Bipolar-I Disorder.

Keywords: Bipolar-I Disorder · Mania · KarXT · adjunctive treatment · mood stabilizer

What participants receive

  • Experimental

    KarXT + Lithium, Valproate, or Lamotrigine

    Drug: Xanomeline/Trospium Chloride

  • Placebo comparator

    Placebo + Lithium, Valproate, or Lamotrigine

    Drug: Placebo

Interventions

  • Xanomeline/Trospium ChlorideDrug

    Also known as KarXT, BMS-986510

    Specified dose on specified days

  • PlaceboDrug

    Specified dose on specified days

What the study measures

Primary outcomes

  1. Change from baseline in Young Mania Rating Scale (YMRS) at Week 5

    Time frame: At Week 5

Secondary outcomes

  1. Change from baseline in Clinical Global Impressions Bipolar (CGI-BP) at Week 5

    Time frame: At Week 5

  2. Occurrence of response at Week 5 assessed as the number of participants with a ≥ 50% decrease from baseline in Young Mania Rating Scale (YMRS) score

    Time frame: At Week 5

  3. Occurrence of response at Week 5 assessed as the number of participants with a ≥ 1 change from baseline in CGI-BP

    Time frame: At Week 5

  4. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to Week 7

  5. Number of participants with Serious Adverse Events (SAEs)

    Time frame: Up to Week 7

  6. Number of participants with TEAEs leading to treatment discontinuation

    Time frame: Up to Week 5

  7. Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to Week 7

  8. Change from baseline in Barnes Akathisia Rating Scale (BARS) at Week 5

    Time frame: At Week 5

  9. Change from baseline in Simpson Angus Scale (SAS) at Week 5

    Time frame: At Week 5

  10. Change from baseline in Abnormal Involuntary Movement Scale (AIMS) at Week 5

    Time frame: At Week 5

  11. Change from baseline in International Prostate Symptom Score (IPSS) at Week 5

    Time frame: At Week 5

Who is running it

Lead sponsor
Bristol-Myers Squibb
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Bristol-Myers Squibb
Data monitoring committee
Yes
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
CN012-0046
Other IDs
2025-521845-26, U1111-1321-1513, 2025
  • Bristol-Myers Squibb

    Study director

    Bristol-Myers Squibb

Study sites(109)

  • Local Institution - 0123

    Madurai, Tamil Nadu, India

    Not yet recruiting

  • Local Institution - 0118

    Kolkata, West Bengal, India

    Not yet recruiting

  • Local Institution - 0116

    Kolkata, India

    Not yet recruiting

  • Local Institution - 0207

    Mangalore, India

    Not yet recruiting

  • Local Institution - 0121

    Mangaluru, Karnataka, India

    Withdrawn

  • Pillar Clinical Research - Bentonville

    Bentonville, Arkansas, United States

    Recruiting

  • Pillar Clinical Research- Little Rock

    Little Rock, Arkansas, United States

    Recruiting

  • Clinical Innovations, Inc. dba CITrials

    Bellflower, California, United States

    Recruiting

  • Inland Psychiatric Medical Group.

    Chino, California, United States

    Recruiting

  • Proscience Research Group

    Culver City, California, United States

    Recruiting

  • Omega Clinical Trials - La Habra

    La Habra, California, United States

    Recruiting

  • Catalina Research Institute, LLC

    Montclair, California, United States

    Recruiting

  • NRC Research Institute

    Orange, California, United States

    Recruiting

  • Clinical Innovations, Inc. dba CITrials

    Riverside, California, United States

    Recruiting

  • Health Synergy Clinical Research

    Boynton Beach, Florida, United States

    Recruiting

  • CenExel iResearch, LLC

    Savannah, Georgia, United States

    Recruiting

  • Pillar Clinical Research -Chicago

    Chicago, Illinois, United States

    Recruiting

  • Arch Clinical Trials

    St Louis, Missouri, United States

    Recruiting

  • Richmond Behavioral Associates

    Staten Island, New York, United States

    Recruiting

  • Community Clinical Research

    Austin, Texas, United States

    Recruiting

  • Adams Clinical Dallas

    DeSoto, Texas, United States

    Recruiting

  • Elevate Clinical Research-Houston

    Houston, Texas, United States

    Recruiting

  • Prime Clinical Research - Mansfield

    Mansfield, Texas, United States

    Recruiting

  • Pillar Clinical Research - Richardson

    Richardson, Texas, United States

    Recruiting

  • Clinica El Jardin

    Santiago del Estero, Argentina

    Recruiting

  • State Psychiatric Hospital Sv. Ivan Rilski Novi Iskar

    Novi Iskar, Bulgaria

    Recruiting

  • "University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski" EAD

    Pleven, Bulgaria

    Recruiting

  • Beijing Anding Hospital - Affiliated Capital University of Medical Science

    Beijing, Beijing Municipality, China

    Recruiting

  • Beijing HuiLongGuan Hospital

    Beijing, Beijing Municipality, China

    Recruiting

  • Guangzhou Brain Hospital

    Guangzhou, Guangdong, China

    Recruiting

  • Hebei Mental Health Center

    Baoding, Hebei, China

    Recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

    Recruiting

  • Nanjing Brain Hospital

    Nanjing, Jiangsu, China

    Recruiting

  • Xi An Mental Health Center

    Xi'an, Shaanxi, China

    Recruiting

  • The Fourth People's Hospital of Chengdu

    Chengdu, Sichuan, China

    Recruiting

  • Tianjin Anding Hospital

    Tianjin, Tianjin Municipality, China

    Recruiting

  • The Affilicated Kangning Hospital of Ningbo University

    Ningbo, Zhejiang, China

    Recruiting

  • Aalborg Universitetshospital Psykiatrien

    Aalborg, North Denmark, Denmark

    Recruiting

  • Glostrup Hospital

    Glostrup Municipality, Denmark

    Recruiting

  • Centre Hospitalier Universitaire de Clermont Ferrand

    Clermont-Ferrand, France

    Recruiting

Showing 40 of 109 sites. 75 recruiting, 25 not recruiting and 9 cancelled; 5 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
Yes
What is shared
Study protocol, Sap, Csr
When
See Plan Description
Access
See Plan Description

BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Source: ClinicalTrials.gov record NCT07140913, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.